{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T11:38:25Z","timestamp":1769341105129,"version":"3.49.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This study assessed the efficacy of chemoradiotherapy for squamous cell carcinoma of the anal canal (SCCAC). Patients with T1\u20134N0-3M0 SCCAC received chemoradiotherapy with 5-fluorouracil (5-FU, 800\u00a0mg\/m2\/day, 96-h infusion) and mitomycin-C (MMC, 10\u00a0mg\/m2 bolus). Patients treated with 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) were administered 36.0\u00a0Gy in 20 fractions or 49.5\u00a0Gy in 33 fractions for elective nodal irradiation and 59.4\u00a0Gy in 33 fractions for primary tumor and metastatic nodal irradiation. The sample size was considered sufficient to estimate 95% confidence intervals (CIs) for the true 2-year disease-free survival (DFS) within a width of +15% when the expected true 2-year DFS was 70%. The primary endpoint was 2-year DFS. The secondary endpoints were 2-year overall survival (OS), locoregional control (LC), colostomy-free survival (CFS) and adverse events. Thirty-one patients were enrolled between January 2014 and July 2019. The median follow-up was 33.3\u00a0months (range, 16.2\u201365.8\u00a0months). Among the 31 patients, 13%, 32%, 16% and 39% had stage I, II, IIIA and IIIB disease, respectively. Thirty patients were treated with IMRT. Complete response (CR) was achieved in 27 patients. The 2-year DFS, OS, LC and CFS rates were 77.4% (95% CI, 58.4\u201388.5%), 93.5% (95% CI, 76.6\u201398.3%), 83.9% (95% CI, 65.5\u201392.9%) and 80.6% (95% CI, 61.9\u201390.8%), respectively. One patient experienced grade 3 late adverse events; however, no grade\u2009\u2265\u20094 late adverse events occurred. Good DFS with a low rate of late adverse events was observed. Chemoradiotherapy with 5-FU and MMC was effective for SCCAC.<\/jats:p>","DOI":"10.1093\/jrr\/rrac069","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T13:24:29Z","timestamp":1664803469000},"page":"154-161","source":"Crossref","is-referenced-by-count":5,"title":["A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10\u20132 trial)"],"prefix":"10.1093","volume":"64","author":[{"given":"Keiko Nemoto","family":"Murofushi","sequence":"first","affiliation":[{"name":"Division of Radiation Oncology , Department of Radiology, , Tokyo 113-8677 , Japan"},{"name":"Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Department of Radiology, , Tokyo 113-8677 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Itasaka","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kurashiki Central Hospital , Okayama 710-8602 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yamaguchi University Graduate School of Medicine , Yamaguchi 755-8505 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima 734-8553 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine , Miyagi 980-8575 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kindai University Faculty of Medicine , Osaka 589-8511 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehiro","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Saitama Cancer Center , Saitama 362-0806 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kyoto Katsura Hospital , Kyoto 615-8256 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Ariga","sequence":"additional","affiliation":[{"name":"Department of Radiology, Graduate School of Medical Science, University of the Ryukyus , Okinawa 903-0215 , Japan"},{"name":"Health Information Management Center, University of the Ryukyus Hospital , Okinawa 903-0215 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuyo","family":"Ogo","sequence":"additional","affiliation":[{"name":"Kurume University Radiation Oncology Center , Fukuoka 830-0011 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology , Department of Radiology, , Tokyo 113-8677 , Japan"},{"name":"Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Department of Radiology, , Tokyo 113-8677 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Jingu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine , Miyagi 980-8575 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Graduate School of Medicine, Osaka University , Osaka 565-0871 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,23]]},"reference":[{"key":"2023012016001807100_ref1","first-page":"68","volume-title":"Cancer Facts and Figures 2012","author":"American Cancer Society","year":"2012"},{"key":"2023012016001807100_ref2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3862\/jcoloproctology.58.415","article-title":"Squamous cell carcinoma of anus and carcinoma association with and fistula in Japan, multi-institutional registration","volume":"58","author":"Sameshima","year":"2005","journal-title":"J Jpn Soc Colo-Proctol"},{"key":"2023012016001807100_ref3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Trial Working Party. Epidermoid and cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research","volume":"348","author":"Cancer","year":"1996","journal-title":"Lancet"},{"key":"2023012016001807100_ref4","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98\u201311 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023012016001807100_ref5","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"2023012016001807100_ref6","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.annonc.2020.06.012","article-title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial","volume":"31","author":"Glynne-Jones","year":"2020","journal-title":"Ann Oncol"},{"key":"2023012016001807100_ref7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s10147-018-1316-1","article-title":"Definitive chemoradiotherapy for anal canal cancer: single-center experience","volume":"23","author":"Tachibana","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2023012016001807100_ref8","first-page":"519","article-title":"Concurrent chemoradiotheraoy for squamous cell carcinoma of the anal canal-report of four cases","volume":"35","author":"Kinjo","year":"2008","journal-title":"Gan To Kagaku Ryoho"},{"key":"2023012016001807100_ref9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10147-009-0892-5","article-title":"Current therapeutic strategies for anal squamous cell carcinoma in Japan","volume":"14","author":"Takashima","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"2023012016001807100_ref10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2023012016001807100_ref11","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER Accord 03 Trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023012016001807100_ref12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomized, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"2023012016001807100_ref13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijrobp.2021.08.008","article-title":"Long-term outcomes of NRG oncology\/RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in anal canal cancer","volume":"112","author":"Kachnic","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023012016001807100_ref14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023012016001807100_ref15","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal canal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and gastrointestinal Cooperative Groups","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"2023012016001807100_ref16","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1002\/cncr.31721","article-title":"Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: a National Cancer Database study","volume":"124","author":"Elson","year":"2018","journal-title":"Cancer"},{"key":"2023012016001807100_ref17","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1200\/JCO.2011.36.1790","article-title":"Cause-specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study","volume":"29","author":"Sunesen","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023012016001807100_ref18","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1200\/JCO.2008.19.6857","article-title":"US intergroup anal carcinoma trial: tumor diameter predicts for colostomy","volume":"27","author":"Ajani","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023012016001807100_ref19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/jpm11050427","article-title":"Concurrent chemoradiation in anal cancer patients delivered with bone marrow sparing IMRT: final results of a prospective phase II trial","volume":"11","author":"Arcadipane","year":"2021","journal-title":"J Pers Med"},{"key":"2023012016001807100_ref20","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.3390\/cancers12113306","article-title":"Bone marrow-sparing IMRT in anal cancer patients undergoing concurrent chemo-radiation: results of the first phase of a prospective phase II trial","volume":"12","author":"Arcadipane","year":"2020","journal-title":"Cancer"},{"key":"2023012016001807100_ref21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12029-020-00393-0","article-title":"Optimal radiotherapy dose in anal cancer: trends in prescription dose and association with survival","volume":"52","author":"Shah","year":"2021","journal-title":"J Gastrointest Cancer"},{"key":"2023012016001807100_ref22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jjco\/hyr028","article-title":"A phase I\/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin-C in patients with clinical stage II\/III squamous cell carcinoma of anal canal (JCOG0903: SMART-AC)","volume":"41","author":"Takashima","year":"2011","journal-title":"Jpn J Clin Oncol"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/64\/1\/154\/48798891\/rrac069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/64\/1\/154\/48798891\/rrac069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T16:01:05Z","timestamp":1674230465000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/64\/1\/154\/6770079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,23]]},"published-print":{"date-parts":[[2023,1,20]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrac069","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1]]},"published":{"date-parts":[[2022,10,23]]}}}